| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 55513-0098-01 | 55513-0098 | Darbepoetin alfa | Aranesp | 10.0 ug/.4mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Oct 6, 2015 | In Use | ||
| 69639-0105-01 | 69639-0105 | Fosnetupitant and Palonosetron | AKYNZEO | 260.0 mg/20mL, 0.28 mg/20mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Intravenous | Jun 15, 2020 | In Use | |
| 70625-0311-01 | 70625-0311 | FOSAPREPITANT | FOSAPREPITANT | 150.0 mg/mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Nov 3, 2021 | In Use | |
| 66758-0036-01 | 66758-0036 | Granisetron | Granisetron | 1.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jun 30, 2008 | May 19, 2020 | No Longer Used |
| 82448-0150-14 | 82448-0150 | Nirogacestat | OGSIVEO | 150.0 mg/1 | Ancillary Therapy | Miscellaneous Agent | Ɣ Secretase Inhibitor | Oral | Nov 27, 2023 | In Use | |
| 68001-0286-39 | 68001-0286 | Leucovorin Calcium | Leucovorin | 20.0 mg/mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Jul 1, 2016 | Feb 1, 2021 | No Longer Used |
| 00069-0294-10 | 00069-0294 | filgrastim-aafi | Nivestym | 480.0 ug/1.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Mar 11, 2019 | In Use | |
| 00069-0324-01 | 00069-0324 | Pegfilgrastim-apgf | NYVEPRIA | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Dec 15, 2020 | In Use | |
| 69639-0103-05 | 69639-0103 | Palonosetron hydrochloride | Aloxi | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Nov 1, 2018 | Nov 1, 2022 | No Longer Used |
| 71335-2974-07 | 71335-2974 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 6, 2026 | In Use | |
| 58160-0830-32 | 58160-0830 | Human Papillomavirus Bivalent Vaccine, Recombinant | Cervarix | 20.0 ug/.5mL, 20.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Oct 16, 2009 | Sep 3, 2013 | No Longer Used |
| 00378-7734-05 | 00378-7734 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | Oct 9, 2014 | No Longer Used |
| 00088-1208-76 | 00088-1208 | Dolasetron mesylate | Anzemet | 12.5 mg/.625mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sep 11, 1997 | Nov 9, 2012 | No Longer Used |
| 00703-7221-01 | 00703-7221 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov 22, 2006 | May 31, 2018 | No Longer Used |
| 73441-0800-04 | 73441-0800 | omidubicel-onlv | OMISIRGE | Ancillary Therapy | Immunostimulant | Stem cell mobilizer | Intravenous | May 1, 2023 | In Use | ||
| 00024-5150-10 | 00024-5150 | Rasburicase | Elitek | Ancillary Therapy | Metabolic Agent | Enzyme | Jul 12, 2002 | In Use | |||
| 80425-0228-03 | 80425-0228 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 22, 2024 | In Use | |
| 68071-1987-02 | 68071-1987 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 23, 2017 | In Use | |
| 80425-0072-05 | 80425-0072 | Ondansetron 4mg, Ondansetron HCL | Ondansetron HCL | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
| 68071-1987-04 | 68071-1987 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 23, 2017 | In Use | |
| 71335-2972-01 | 71335-2972 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 29, 2025 | In Use | |
| 71837-5843-05 | 71837-5843 | SARGRAMOSTIM | Leukine | 250.0 ug/mL | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | Intravenous, Subcutaneous | Sep 1, 2023 | In Use | |
| 43288-0104-10 | 43288-0104 | Ondansetron | Zuplenz | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 5, 2010 | Nov 30, 2015 | No Longer Used | |
| 80425-0072-02 | 80425-0072 | Ondansetron 4mg, Ondansetron HCL | Ondansetron HCL | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
| 51672-4138-00 | 51672-4138 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 28, 2010 | May 28, 2010 | In Use |
Found 12611 results — Export these results
Home